Factors associated with hematological adverse reactions of drugs authorized via the centralized procedure

• Published in: Scientific reports 2024-04, Vol.14 (1), p.9074-9074, Article 9074
• Main Authors: Stević, Ivana, Janković, Slobodan M., Georgiev, Andrijana Milošević, Marinković, Valentina, Lakić, Dragana
• Format: Article
• Language: English
• Subjects: 631/154/1438; 631/154/155; 692/499; 692/700/155; 692/700/478/174; 692/700/565/2194; Anemia; Anemia - chemically induced; Anemia - drug therapy; Biological products; Biosimilar Pharmaceuticals - adverse effects; Centralized procedure; Drug Approval; Drug-Related Side Effects and Adverse Reactions - epidemiology; Drug-Related Side Effects and Adverse Reactions - etiology; Drugs; Drugs, Essential; Drugs, Generic; Hematological adverse drug reaction; Hematology; Humanities and Social Sciences; Humans; Leukopenia; Leukopenia - chemically induced; multidisciplinary; Pharmaceutical Preparations; Regulatory factors; Science; Science (multidisciplinary); Side effects; Statistical analysis; Thrombocytopenia; Thrombocytopenia - chemically induced
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-024-59710-3

Serious hematological adverse drug reactions (HADRs) may lead to or prolong hospitalization and even cause death. The aim of this study was to determine the regulatory factors associated with HADRs caused by drugs that were authorized up to July 2023 by the European Medicines Agency (EMA) and to evaluate the frequency of HADRs. Using a cross-sectional approach, the type and frequency of HADRs were collected from the Summaries of Product Characteristics of Drugs Authorized by the EMA and analyzed within proprietary, nonproprietary, and biosimilar/biological frameworks. Multivariate statistical analysis was used to investigate the associations of generic status, biosimilar status, conditional approval, exceptional circumstances, accelerated assessment, orphan drug status, years on the market, administration route, and inclusion on the Essential Medicines List (EML) with HADRs. In total, 54.78% of proprietary drugs were associated with HADRs at any frequency, while anemia, leucopenia, and thrombocytopenia were observed in approximately 36% of the patients. The predictors of any HADR, anemia, and thrombocytopenia of any frequency are generic status, biosimilar status, and inclusion on the EML, while the only protective factor is the administration route. Biosimilars and their originator biologicals have similar frequencies of HADRs; the only exception is somatropin. Knowledge of the regulatory factors associated with HADRs could help clinicians address monitoring issues when new drugs are introduced for the treatment of patients.